Nuveen LLC Invests $733,000 in MaxCyte, Inc. $MXCT

Nuveen LLC acquired a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 268,541 shares of the company’s stock, valued at approximately $733,000. Nuveen LLC owned about 0.25% of MaxCyte as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of MXCT. AXA S.A. bought a new position in MaxCyte in the 4th quarter worth about $4,105,000. Gagnon Advisors LLC acquired a new stake in MaxCyte during the first quarter valued at approximately $2,550,000. Chevy Chase Trust Holdings LLC lifted its stake in MaxCyte by 66.5% during the first quarter. Chevy Chase Trust Holdings LLC now owns 2,230,182 shares of the company’s stock valued at $6,088,000 after purchasing an additional 890,353 shares during the last quarter. Gagnon Securities LLC raised its holdings in shares of MaxCyte by 431.3% during the first quarter. Gagnon Securities LLC now owns 1,048,318 shares of the company’s stock valued at $2,862,000 after acquiring an additional 850,992 shares during the period. Finally, Royce & Associates LP raised its holdings in shares of MaxCyte by 30.1% during the first quarter. Royce & Associates LP now owns 1,040,873 shares of the company’s stock valued at $2,842,000 after acquiring an additional 241,000 shares during the period. Institutional investors own 68.81% of the company’s stock.

Insider Transactions at MaxCyte

In related news, Director Richard Douglas acquired 80,000 shares of the stock in a transaction on Wednesday, August 13th. The stock was purchased at an average price of $1.39 per share, for a total transaction of $111,200.00. Following the transaction, the director owned 230,577 shares of the company’s stock, valued at $320,502.03. The trade was a 53.13% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William W. Brooke acquired 50,000 shares of the stock in a transaction on Wednesday, August 13th. The stock was bought at an average price of $1.29 per share, with a total value of $64,500.00. Following the transaction, the director directly owned 150,879 shares in the company, valued at approximately $194,633.91. This represents a 49.56% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 355,000 shares of company stock worth $479,950. Corporate insiders own 3.30% of the company’s stock.

MaxCyte Stock Down 3.6%

Shares of MXCT stock opened at $1.34 on Wednesday. MaxCyte, Inc. has a 12-month low of $1.26 and a 12-month high of $5.20. The company has a market capitalization of $142.86 million, a P/E ratio of -3.12 and a beta of 1.20. The firm has a 50-day moving average price of $1.88 and a 200 day moving average price of $2.44.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%. The firm had revenue of $8.51 million for the quarter, compared to the consensus estimate of $9.57 million. As a group, research analysts expect that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MXCT. Stephens started coverage on shares of MaxCyte in a research note on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price objective on the stock. BTIG Research reiterated a “neutral” rating on shares of MaxCyte in a research note on Monday, August 11th. William Blair downgraded shares of MaxCyte from an “outperform” rating to a “market perform” rating in a report on Thursday, August 7th. Finally, Wall Street Zen downgraded shares of MaxCyte from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, MaxCyte currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.